Accreditation Expired
FSGS: Current and future therapies
GlobalAn expert opinion on the potential clinical implications of current and investigational therapies for FSGS.
FSGS: Current and future therapies
Historically, treatment options for focal segmental glomerulosclerosis (FSGS) have been limited to high-dose corticosteroids or calcineurin inhibitors in those ineligible or intolerant to steroids. However, an increase in clinical trial activity in the field of kidney disease may carry hope for novel therapeutic options for FSGS. This is illustrated by the recent approval of dapagliflozin for chronic kidney disease.
In this video, Dr. Kirk Campbell offers his expert opinion into the potential clinical implications of current and investigational therapies, both now and in the future. Dr. Kirk Campbell is Professor of Medicine; Vice Chair for Diversity, Equity and Inclusion; and Director of the Nephrology Fellowship Program at the Icahn School of Medicine at Mount Sinai in New York.
By completing this module, you can qualify for 0.25 CME credits. To claim your credits, you must watch the video and successfully pass the post-module assessment.
Pre-Activity Information
Nephrologists
After taking part in this activity, learners will be able to discuss the mechanism of action and clinical trial data of potential new treatments, including ETA and AT1 receptor antagonists.
Faculty: Dr. Kirk Campbell
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Consultant | Travere, ANI, Chinook, Calliditas |
| Research/Grant Support | Vertex |
Staff Disclosures
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The content for this activity was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational or Experimental Drug Use: Atresentan, cyclosporine, empagliflozin, sparsentan are mentioned in the context of the treatment of focal segmental glomerulosclerosis.
This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME and validated by an independent steering committee; Travere Therapeutics has had no influence on the content of this education.
This module was accredited on 20th October 2022 and will expire on 20th October 2023.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.